NCT05506410招募中不适用
A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
Zhengzhou University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年8月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- progression free survival（PFS）
研究概览
简要总结
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-70, ECOG score 0-2;
- •Estimated survival time >6 months;
- •Mantle cell lymphoma was confirmed by pathology.
- •Acceptable hematological indexes without chemotherapy contraindications; Neutrophil absolute value ≥1.0×10^9 /L, PLT≥75×10^9 /L, hemoglobin ≥80g/L (except patients with lymphoma bone marrow infiltration);
- •At least one measurable lesion. For intrnodal lesions, they were defined as long diameter ≥1.5cm and short diameter ≥1.0cm; For r extranodal lesions, the length should be ≥1.0cm;
- •Liver function: TBIL≤1.5×ULN; ALT or AST ≤2.5 x ULN; Alkaline phosphatase ≤3×ULN in patients with non-bone invasion;
- •Kidney function: serum creatinine ≤1.5×ULN;
- •Excluding other major diseases, the heart function is normal;
- •10 Women and men of childbearing age and their spouses are willing to use adequate contraception throughout the study period, and women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose;
- •11 Subjects voluntarily participated in the clinical trial, signed the informed consent form, and cooperated with the follow-up;
- •There is no other relevant treatment including traditional Chinese medicine (anti-tumor), immunotherapy, biologic therapy (except anti-bone metastasis and other symptoms);
排除标准
- •Patients with definite neuropathy or psychosis, including dementia or seizures, a history of psychotropic substance abuse and inability to abstinence, or other substantial lesions that may increase CNS toxicity;
- •Participating in other clinical trials or participating in other clinical investigators 4 weeks before enrollment (except those not receiving treatment);
- •Systemic autoimmune disease or immune deficiency;
- •Refusing to collect blood samples;
- •Allergic to any drug in the protocol;
- •Pregnant and lactating women;
- •Major diseases that can cause test interference and uncontrolled active infected persons;
- •Primary or secondary central tumor;
- •Contraindications to chemotherapy;
- •Not considered suitable for inclusion.
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infections (other than nail bed skin fungal infections) or any major systemic infection event requiring intravenous antibiotic treatment or hospitalization (other than neoplastic fever) within 4 weeks prior to enrollment;
- •Application of other antitumor therapies (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy);
- •Other serious medical conditions that may limit the subject's participation in the study, such as uncontrolled diabetes; Severe cardiac insufficiency (NYHA grade II or above); Acute coronary syndrome in the last 6 months; Coronary revascularization such as stenting, cabG, and other cardiac and macrovascular procedures within the last 6 months; Severe arrhythmias include frequent ventricular premature, ventricular tachycardia, rapid atrial fibrillation/flutter, and severe bradycardia. Uncontrolled hypertension: systolic blood pressure >150mmHg, diastolic blood pressure >100mmHg. Gastric ulcers (those identified by the investigators as being at risk for perforation); Active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, etc.); Severe respiratory diseases (e.g. obstructive pulmonary disease and history of bronchospasm), etc.;
- •Hemophagocytic cell syndrome;
- •Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) was positive, and the peripheral blood hepatitis B virus (HBV) DNA titer was not within the normal reference range; Hepatitis C virus (HCV) antibody positive and HCV RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA test positive; Who tested positive for syphilis.
研究组 & 干预措施
Arms
Experimental:Rituximab、Bendamustine、Cytarabine、Prednisone （R-BAP） combined with BTK inhibitors To observe the efficacy and safety of R-BAP combined with BTK inhibitors in the treatment of newly-treated patients with mantle cell lymphoma (MCL)
干预措施: Rituximab (Drug)
结局指标
主要结局
progression free survival（PFS）
时间窗: two years
progression free survival
次要结局
- CRR(two years)
- OS(two years)
- ORR(two years)
- ADR(two years)
研究者
Mingzhi Zhang
Director of the Oncology Department, The First Affiliated Hospital of Zhengzhou University
Zhengzhou University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's SyndromeChronic Lymphocytic LeukemiaProlymphocytic LeukemiaNCT02029443Acerta Pharma BV306
招募中
1 期
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System LymphomaPrimary Central Nervous System LymphomaNCT04831658Mingzhi Zhang40
进行中（未招募）
2 期
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT04505254M.D. Anderson Cancer Center60
招募中
2 期
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMWaldenstrom MacroglobulinemiaNCT05914662Institute of Hematology & Blood Diseases Hospital, China42
进行中（未招募）
2 期
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT04783415City of Hope Medical Center12